Dose Equivalent: Jardiance 10 mg to Farxiga
Switch from Jardiance (empagliflozin) 10 mg once daily to Farxiga (dapagliflozin) 10 mg once daily. This represents the standard dose-for-dose conversion between these two SGLT2 inhibitors.
Dosing Rationale
The FDA-approved dosing for both medications establishes clear equivalence 1, 2:
- Jardiance: Standard dose is 10 mg once daily, with option to increase to 25 mg for additional glycemic control 2
- Farxiga: Standard dose ranges from 5-10 mg once daily for glycemic control, with 10 mg being the standard dose for cardiovascular and renal indications 1
For direct conversion: Jardiance 10 mg = Farxiga 10 mg once daily
Clinical Context for Switching
Both agents are SGLT2 inhibitors with similar mechanisms of action and are listed together in the 2025 ADA guidelines as having comparable benefits for MACE, heart failure, and CKD 3. The guidelines make no distinction between individual SGLT2 inhibitors in terms of dosing equivalence.
Key Considerations:
- Glycemic efficacy: Some real-world data suggest empagliflozin 25 mg may produce slightly greater HbA1c reductions than dapagliflozin 10 mg (approximately 0.5% difference) 4, 5, but this comparison is between different dose levels, not the standard 10 mg doses
- Cardiovascular outcomes: Recent real-world evidence shows comparable safety profiles, though one 2026 study suggested potential differences in MACE outcomes 6, 7
- Side effect profile: Empagliflozin may have slightly higher rates of genital tract infections and phimosis compared to dapagliflozin, though absolute risk differences are small 8
Practical Switching Algorithm
- Discontinue Jardiance 10 mg
- Start Farxiga 10 mg once daily the next day (no washout period needed)
- Monitor within 2-4 weeks for:
- Volume status and blood pressure (both drugs cause diuresis)
- Renal function (eGFR)
- Glycemic control if used for diabetes
- Genital/urinary symptoms
Renal Function Adjustments:
- eGFR ≥45 mL/min/1.73 m²: Use standard 10 mg dose for all indications 1
- eGFR 25-44 mL/min/1.73 m²: Continue 10 mg for heart failure/CKD indications; not recommended for glycemic control 1
- eGFR <25 mL/min/1.73 m²: Do not initiate, but may continue if already on therapy for CKD/HF benefits 1
Important Caveats
- Both medications require temporary discontinuation 3-4 days before major surgery 1, 2
- Maintain vigilance for ketoacidosis risk, particularly in insulin-deficient states 1, 2
- Ensure adequate hydration and volume status before and after switching 1, 2
- The 10 mg to 10 mg conversion is appropriate for all FDA-approved indications (heart failure, CKD, diabetes with CV disease) 1, 2